Us Fda Approves Vertexs Kalydeco To Treat Eligible Infants With Cf Ages 1 Month And Older
Vertex Pharmaceuticals Incorporated Announced The Us Food And Drug Administration (Fda) Approved Kalydeco (Ivacaftor) For Use In Children With Cystic Fibrosis (Cf) Ages 1 Month To Less Than Four Months Old Who Have At Least One Mutation In Their Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene That Is Responsive To Kalydeco Based On Clinical And/Or In Vitro Assay Data.Kalydeco Is Already Approved In The Us And Eu For The Treatment Of Cf In Patients Ages Four Months And Older.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!